Table of Contents
Scholarly Research Exchange
Volume 2008 (2008), Article ID 620489, 6 pages
http://dx.doi.org/10.3814/2008/620489
Research Article

Drug-Drug Interaction between Pravastatin and Gliclazide in Animal Models

1Pharmacology Division, College of Pharmaceutical Sciences, Andhra University, Visakhapatnam 530003, India
2Pharmacology Division, Government College of Pharmacy, Bangalore 560027, India

Received 17 May 2008; Revised 31 May 2008; Accepted 15 August 2008

Copyright © 2008 S. Satyanarayana et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. M. Gribble, S. J. Tucker, S. Seino, and F. M. Ashcroft, “Tissue specificity of sulfonylureas studies on cloned cardiac and β- cell KATP channels,” Diabetes, vol. 47, no. 9, pp. 1412–1418, 1998. View at Publisher · View at Google Scholar
  2. A. D. Harrower, “Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM,” Diabetes Research and Clinical Practice, vol. 14, pp. S65–S67, 1991. View at Publisher · View at Google Scholar
  3. O. Ziegler and P. Drouin, “Hemobiological properties of gliclazide,” Journal of Diabetes and Its Complications, vol. 8, no. 4, pp. 235–239, 1994. View at Publisher · View at Google Scholar
  4. H. Y. Pan, A. R. DeVault, B. J. Swites et al., “Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia,” Clinical Pharmacology and Therapeutics, vol. 48, no. 2, pp. 201–207, 1990. View at Google Scholar
  5. I. Hsu, S. A. Spinler, and N. E. Johnson, “Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia,” Annals of Pharmacotherapy, vol. 29, no. 7-8, pp. 743–759, 1995. View at Google Scholar
  6. T. Hatanaka, “Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events,” Clinical Pharmacokinetics, vol. 39, no. 6, pp. 397–412, 2000. View at Publisher · View at Google Scholar
  7. W. Jacobsen, G. Kirchner, K. Hallensleben et al., “Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver,” Drug Metabolism and Disposition, vol. 27, no. 2, pp. 173–179, 1999. View at Google Scholar
  8. C. Transon, T. Leemann, and P. Dayer, “In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors,” European Journal of Clinical Pharmacology, vol. 50, no. 3, pp. 209–215, 1996. View at Publisher · View at Google Scholar
  9. V. Riley, “Adaptation of orbital bleeding technic to rapid serial blood studies,” Proceedings of the Society for Experimental Biology and Medicine, vol. 104, pp. 751–754, 1960. View at Google Scholar
  10. P. Trinder, “Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen,” Journal of Clinical Pathology, vol. 22, no. 2, pp. 158–161, 1969. View at Publisher · View at Google Scholar
  11. R. E. Heikkila, “The prevention of alloxan-induced diabetes in mice by dimethyl sulfoxide,” European Journal of Pharmacology, vol. 44, no. 2, pp. 191–193, 1977. View at Publisher · View at Google Scholar
  12. K. Eswar Kumar, A. Ramesh, R. S. Yadav, and S. Satyanarayana, “Determination of gliclazide in rabbit serum by RP-HPLC,” Acta Ciencia Indica. Chemistry, vol. 33, no. 3, pp. 273–278, 2007. View at Google Scholar
  13. H. Miyazaki, T. Fujii, K. Yoshida, S. Arakawa, and H. Furukawa, “Disposition and metabolism of [H3]gliclazide in rats,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 8, no. 2, pp. 117–131, 1983. View at Google Scholar
  14. A. Benakis and B. Glasson, “Metabolic study of 14 C-labelled gliclazide in normal rats and in rats with streptozotocin-induced diabetes,” in Gliclazide and Treatment of Diabetes, H. Keen, Ed., pp. 57–69, Academic Press and the Royal Society of Medicine, London, UK, 1980. View at Google Scholar
  15. D. E. Rollins and C. D. Klaassen, “Biliary excretion of drugs in man,” Clinical Pharmacokinetics, vol. 4, no. 5, pp. 368–379, 1979. View at Google Scholar
  16. D. B. Campbell, R. Lavielle, and C. Nathan, “The mode of action and clinical pharmacology of gliclazide: a review,” Diabetes Research and Clinical Practice, vol. 14, pp. S21–S36, 1991. View at Publisher · View at Google Scholar
  17. B. L. Wajchenberg, A. T. M. G. Santomauro, and R. N. Porrelli, “Effect of a sulfonylurea (gliclazide) treatment on insulin sensitivity and glucose-mediated glucose disposal in patients with non-insulin-dependent diabetes mellitus (NIDDM),” Diabetes Research and Clinical Practice, vol. 20, no. 2, pp. 147–154, 1993. View at Publisher · View at Google Scholar
  18. S. M. Singhvi, H. Y. Pan, R. A. Morrison, and D. A. Willard, “Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects,” British Journal of Clinical Pharmacology, vol. 29, no. 2, pp. 239–243, 1990. View at Google Scholar
  19. R. E. Ferner and S. Chaplin, “The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs,” Clinical Pharmacokinetics, vol. 12, no. 6, pp. 379–401, 1987. View at Google Scholar
  20. T. Oida, K. Yoshida, A. Kagemoto, Y. Sekine, and T. Higashijima, “The metabolism of gliclazide in man,” Xenobiotica, vol. 15, no. 1, pp. 87–96, 1985. View at Google Scholar